Shire Plc American Depositary Shares (SHPG) 185.80 $SHPG
AbbVie Drops Shire Deal, Announces Buyback, Ups Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 3:32PM CDT
AbbVie Inc. (ABBV) has jointly agreed with Shire to terminate the planned acquisition of the latter, which was due to be completed by year end.
LCI: 44.96 (+1.04), SHPG: 185.80 (+1.21), ABBV: 56.29 (+1.88), ENTA: 41.83 (-4.76)
Shire to announce third quarter 2014 results
M2 - Tue Oct 21, 11:27AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) will announce third quarter 2014 earnings on Friday October 24, 2014.
SHPG: 185.80 (+1.21)
Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 74.71 (+3.71), ALNY: 88.92 (+0.93), SRPT: 22.49 (-0.34), SHPG: 185.80 (+1.21), NPSP: 28.69 (+0.24)
Merger Deal Updates, Dividend, Dispute Settlement, Regulatory Application Submission, and Preliminary Results - Research Reports on Shire, Johnson & Johnson, Merck, Amgen and HCA
PR Newswire - Tue Oct 21, 8:00AM CDT
Today, Analysts Review released its research reports regarding Shire plc (NASDAQ: SHPG), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Amgen Inc. (NASDAQ: AMGN) and HCA Holdings, Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7333-100free.
HCA: 71.61 (+1.15), JNJ: 100.36 (+1.16), MRK: 55.13 (+1.08), SHPG: 185.80 (+1.21), AMGN: 144.09 (+6.58), ABBV: 56.29 (+1.88)
European Stocks Rise as Corporate Earnings Overshadow Macro Concerns
at The Street - Tue Oct 21, 5:31AM CDT
European stock indices rise as a stream of corporate updates distracted investors from wider macro-economic and geopolitical worries.
TOT: 56.99 (+1.58), SHPG: 185.80 (+1.21), TM: 113.35 (+0.04), ABBV: 56.29 (+1.88)
ABBVIE
at Investor's Business Daily - Mon Oct 20, 5:57PM CDT
ABBVIE (ABBV), a drugmaker, terminated a planned merger with Ireland-based Shire (SHPG). AbbVie also OK'd a new $5 bil share buyback and lifted its quarterly dividend 17% to 49 cents. AbbVie shares rose 1.5% to 55.25. Shire fell 0.8% to 183.20.
SHPG: 185.80 (+1.21), ABBV: 56.29 (+1.88)
AbbVie to pay Shire $1.64B fee over nixed merger
AP - Mon Oct 20, 5:27PM CDT
NORTH CHICAGO, Ill. (AP) — AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee.
1 Comment
SHPG: 185.80 (+1.21)
Sanofi and Regeneron Dose Patients in Dupilumab Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 4:45PM CDT
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the first patients have been dosed in a phase III study, LIBERTY AD CHRONOS, on pipeline candidate dupilumab.
AGN: 186.16 (+6.91), SHPG: 185.80 (+1.21), SNY: 52.15 (+0.37), REGN: 381.01 (+14.88)
Shire plc: AbbVie Terminates Offer for Shire
PR Newswire - Mon Oct 20, 4:22PM CDT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
SHPG: 185.80 (+1.21)
Leon Cooperman Says Stocks Still Better Than Bonds, There's No Recession
at The Street - Mon Oct 20, 1:40PM CDT
Hedge fund manager Leon Cooperman sees stocks as fairly valued and a much better investment than fixed-income.
HAS: 57.72 (+1.21), VRX: 130.38 (+5.60), AXP: 85.64 (+1.63), HON: 92.92 (+2.92), VFC: 66.67 (+2.71), HAL: 55.66 (+2.74), TLT: 120.54 (-0.97), HPQ: 34.74 (+0.92), AGN: 186.16 (+6.91), JNJ: 100.36 (+1.16), SPY: 194.07 (+3.77), GS: 180.18 (+2.34), QQQ: 96.87 (+2.48), QEP: 24.60 (+0.43), IBM: 163.23 (-5.87), SHPG: 185.80 (+1.21), BPL: 78.50 (+2.22), DIA: 165.80 (+2.15), PFF: 39.55 (+0.10), CRUS: 21.16 (+0.13), GOOGL: 538.03 (+5.65), IWM: 110.53 (+1.79), AAPL: 102.47 (+2.71)
3 Stocks I'll Buy if the Market Crashes
George Budwell, The Motley Fool - Motley Fool - Mon Oct 20, 12:01PM CDT
After a monstrous bull run of late, the stock market finally started to pullback. The Nasdaq Biotechnology Index , for instance, fell by nearly 7% last week alone: Even so, it's important to keep the magnitude of this week's drop in...
ACAD: 26.77 (+0.19), GILD: 106.67 (+4.46), SHPG: 185.80 (+1.21), NPSP: 28.69 (+0.24), IBB: 278.27 (+8.68), ABBV: 56.29 (+1.88)
Cramer Reviews His Top 10 List for a Market Recovery: Boxes Checked!
at The Street - Mon Oct 20, 10:33AM CDT
We now have an investable bottom on our hands.
GE: 25.45 (+0.42), HON: 92.92 (+2.92), XLNX: 43.21 (+1.55), SHPG: 185.80 (+1.21), GOOGL: 538.03 (+5.65), ABBV: 56.29 (+1.88), TXT: 37.54 (+1.09), SNDK: 88.63 (+4.25), SLB: 97.75 (+3.15), MS: 34.06 (+0.74), BHI: 54.23 (+1.58)
Interim Chief Financial Officer James Bowling to Step Down
M2 - Mon Oct 20, 10:29AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that James Bowling, Interim Chief Financial Officer (CFO), has notified the Board of Directors of his decision to step down from his current role to pursue a new career opportunity as CFO of Severn Trent plc. James will leave Shire at the end of Q1 2015 and the company will commence a search for a new CFO immediately.
SHPG: 185.80 (+1.21)
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna
PR Newswire - Mon Oct 20, 7:35AM CDT
Today, Analysts Review released its research reports regarding AbbVie Inc. (NYSE: ABBV), Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7291-100free.
GILD: 106.67 (+4.46), PFE: 28.28 (+0.35), SHPG: 185.80 (+1.21), LLY: 64.68 (+1.58), ABBV: 56.29 (+1.88), AET: 78.39 (+1.94)
Research and Markets: United States Tissue Engineered - Skin Substitutes Market Outlook 2020: Key Players are Organogenesis, Inc., Shire Plc and Kinetic Concepts, Inc
Business Wire - Mon Oct 20, 7:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sqjx76/united_states) has announced the addition of the "United States Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering.
SHPG: 185.80 (+1.21)
United States Tissue Engineered - Skin Substitutes Market Outlook 2020: Key Players are Organogenesis, Inc., Shire Plc and Kinetic Concepts, Inc
M2 - Mon Oct 20, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zjtfrc/united_states) has announced the addition of the "United States Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "United States Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the United States Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. Scope - Market size data for Tissue Engineered - Skin Substitutes market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes. - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Tissue Engineered - Skin Substitutes market. - Global corporate-level profiles of key companies operating within the United States Tissue Engineered - Skin Substitutes. - Key players covered include Organogenesis, Inc., Shire Plc and Kinetic Concepts, Inc. For more information visit http://www.researchandmarkets.com/research/zj...ted_states
SHPG: 185.80 (+1.21)
Texas Medicaid Fraud Attorney at Brewer & Pritchard, P.C., Weighs in on $56.5 Million Settlement Involving Alleged False Claims Act Violations
PRWeb - Sat Oct 18, 1:01AM CDT
Medicaid fraud attorney J. Mark Brewer of Brewer & Pritchard, P.C., today said a recent $56.5 million settlement involving allegations of fraud by Shire Pharmaceuticals LLC illustrates how a whistleblower's action can make a significant difference.
SHPG: 185.80 (+1.21)
Astellas Files for Amendment of Isavuconazole Study Protocol - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:15PM CDT
Astellas Pharma, Inc. (ALPMY) submitted an amendment for its phase III study (ACTIVE) protocol on isavuconazole for invasive fungal infections.
LCI: 44.96 (+1.04), SHPG: 185.80 (+1.21), PCRX: 100.85 (+1.94)
Roche Reports Strong Sales Results for 9 Months of 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 9:49AM CDT
Roche (RHHBY) reported encouraging sales results for the first nine months of 2014.
AGN: 186.16 (+6.91), SHPG: 185.80 (+1.21), NVS: 88.61 (+0.71)
AbbVie Drops Shire Deal, Announces Buyback, Ups Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 3:32PM CDT
AbbVie Inc. (ABBV) has jointly agreed with Shire to terminate the planned acquisition of the latter, which was due to be completed by year end.
LCI: 44.96 (+1.04), SHPG: 185.80 (+1.21), ABBV: 56.29 (+1.88), ENTA: 41.83 (-4.76)
Shire to announce third quarter 2014 results
M2 - Tue Oct 21, 11:27AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) will announce third quarter 2014 earnings on Friday October 24, 2014.
SHPG: 185.80 (+1.21)
Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 74.71 (+3.71), ALNY: 88.92 (+0.93), SRPT: 22.49 (-0.34), SHPG: 185.80 (+1.21), NPSP: 28.69 (+0.24)
Merger Deal Updates, Dividend, Dispute Settlement, Regulatory Application Submission, and Preliminary Results - Research Reports on Shire, Johnson & Johnson, Merck, Amgen and HCA
PR Newswire - Tue Oct 21, 8:00AM CDT
Today, Analysts Review released its research reports regarding Shire plc (NASDAQ: SHPG), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Amgen Inc. (NASDAQ: AMGN) and HCA Holdings, Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7333-100free.
HCA: 71.61 (+1.15), JNJ: 100.36 (+1.16), MRK: 55.13 (+1.08), SHPG: 185.80 (+1.21), AMGN: 144.09 (+6.58), ABBV: 56.29 (+1.88)
European Stocks Rise as Corporate Earnings Overshadow Macro Concerns
at The Street - Tue Oct 21, 5:31AM CDT
European stock indices rise as a stream of corporate updates distracted investors from wider macro-economic and geopolitical worries.
TOT: 56.99 (+1.58), SHPG: 185.80 (+1.21), TM: 113.35 (+0.04), ABBV: 56.29 (+1.88)
ABBVIE
at Investor's Business Daily - Mon Oct 20, 5:57PM CDT
ABBVIE (ABBV), a drugmaker, terminated a planned merger with Ireland-based Shire (SHPG). AbbVie also OK'd a new $5 bil share buyback and lifted its quarterly dividend 17% to 49 cents. AbbVie shares rose 1.5% to 55.25. Shire fell 0.8% to 183.20.
SHPG: 185.80 (+1.21), ABBV: 56.29 (+1.88)
AbbVie to pay Shire $1.64B fee over nixed merger
AP - Mon Oct 20, 5:27PM CDT
NORTH CHICAGO, Ill. (AP) — AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee.
1 Comment
SHPG: 185.80 (+1.21)
Sanofi and Regeneron Dose Patients in Dupilumab Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 4:45PM CDT
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the first patients have been dosed in a phase III study, LIBERTY AD CHRONOS, on pipeline candidate dupilumab.
AGN: 186.16 (+6.91), SHPG: 185.80 (+1.21), SNY: 52.15 (+0.37), REGN: 381.01 (+14.88)
Shire plc: AbbVie Terminates Offer for Shire
PR Newswire - Mon Oct 20, 4:22PM CDT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
SHPG: 185.80 (+1.21)
Leon Cooperman Says Stocks Still Better Than Bonds, There's No Recession
at The Street - Mon Oct 20, 1:40PM CDT
Hedge fund manager Leon Cooperman sees stocks as fairly valued and a much better investment than fixed-income.
HAS: 57.72 (+1.21), VRX: 130.38 (+5.60), AXP: 85.64 (+1.63), HON: 92.92 (+2.92), VFC: 66.67 (+2.71), HAL: 55.66 (+2.74), TLT: 120.54 (-0.97), HPQ: 34.74 (+0.92), AGN: 186.16 (+6.91), JNJ: 100.36 (+1.16), SPY: 194.07 (+3.77), GS: 180.18 (+2.34), QQQ: 96.87 (+2.48), QEP: 24.60 (+0.43), IBM: 163.23 (-5.87), SHPG: 185.80 (+1.21), BPL: 78.50 (+2.22), DIA: 165.80 (+2.15), PFF: 39.55 (+0.10), CRUS: 21.16 (+0.13), GOOGL: 538.03 (+5.65), IWM: 110.53 (+1.79), AAPL: 102.47 (+2.71)
3 Stocks I'll Buy if the Market Crashes
George Budwell, The Motley Fool - Motley Fool - Mon Oct 20, 12:01PM CDT
After a monstrous bull run of late, the stock market finally started to pullback. The Nasdaq Biotechnology Index , for instance, fell by nearly 7% last week alone: Even so, it's important to keep the magnitude of this week's drop in...
ACAD: 26.77 (+0.19), GILD: 106.67 (+4.46), SHPG: 185.80 (+1.21), NPSP: 28.69 (+0.24), IBB: 278.27 (+8.68), ABBV: 56.29 (+1.88)
Cramer Reviews His Top 10 List for a Market Recovery: Boxes Checked!
at The Street - Mon Oct 20, 10:33AM CDT
We now have an investable bottom on our hands.
GE: 25.45 (+0.42), HON: 92.92 (+2.92), XLNX: 43.21 (+1.55), SHPG: 185.80 (+1.21), GOOGL: 538.03 (+5.65), ABBV: 56.29 (+1.88), TXT: 37.54 (+1.09), SNDK: 88.63 (+4.25), SLB: 97.75 (+3.15), MS: 34.06 (+0.74), BHI: 54.23 (+1.58)
Interim Chief Financial Officer James Bowling to Step Down
M2 - Mon Oct 20, 10:29AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that James Bowling, Interim Chief Financial Officer (CFO), has notified the Board of Directors of his decision to step down from his current role to pursue a new career opportunity as CFO of Severn Trent plc. James will leave Shire at the end of Q1 2015 and the company will commence a search for a new CFO immediately.
SHPG: 185.80 (+1.21)
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna
PR Newswire - Mon Oct 20, 7:35AM CDT
Today, Analysts Review released its research reports regarding AbbVie Inc. (NYSE: ABBV), Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7291-100free.
GILD: 106.67 (+4.46), PFE: 28.28 (+0.35), SHPG: 185.80 (+1.21), LLY: 64.68 (+1.58), ABBV: 56.29 (+1.88), AET: 78.39 (+1.94)
Research and Markets: United States Tissue Engineered - Skin Substitutes Market Outlook 2020: Key Players are Organogenesis, Inc., Shire Plc and Kinetic Concepts, Inc
Business Wire - Mon Oct 20, 7:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sqjx76/united_states) has announced the addition of the "United States Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering.
SHPG: 185.80 (+1.21)
United States Tissue Engineered - Skin Substitutes Market Outlook 2020: Key Players are Organogenesis, Inc., Shire Plc and Kinetic Concepts, Inc
M2 - Mon Oct 20, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zjtfrc/united_states) has announced the addition of the "United States Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "United States Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the United States Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. Scope - Market size data for Tissue Engineered - Skin Substitutes market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes. - Annualized market revenues (USD million), volume (units) and average prices (in US dollars) data for each of the market segments. Data is provided from 2005 to 2013 and forecast to 2020. - 2013 company shares and distribution shares data for Tissue Engineered - Skin Substitutes market. - Global corporate-level profiles of key companies operating within the United States Tissue Engineered - Skin Substitutes. - Key players covered include Organogenesis, Inc., Shire Plc and Kinetic Concepts, Inc. For more information visit http://www.researchandmarkets.com/research/zj...ted_states
SHPG: 185.80 (+1.21)
Texas Medicaid Fraud Attorney at Brewer & Pritchard, P.C., Weighs in on $56.5 Million Settlement Involving Alleged False Claims Act Violations
PRWeb - Sat Oct 18, 1:01AM CDT
Medicaid fraud attorney J. Mark Brewer of Brewer & Pritchard, P.C., today said a recent $56.5 million settlement involving allegations of fraud by Shire Pharmaceuticals LLC illustrates how a whistleblower's action can make a significant difference.
SHPG: 185.80 (+1.21)
Astellas Files for Amendment of Isavuconazole Study Protocol - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:15PM CDT
Astellas Pharma, Inc. (ALPMY) submitted an amendment for its phase III study (ACTIVE) protocol on isavuconazole for invasive fungal infections.
LCI: 44.96 (+1.04), SHPG: 185.80 (+1.21), PCRX: 100.85 (+1.94)
Roche Reports Strong Sales Results for 9 Months of 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 9:49AM CDT
Roche (RHHBY) reported encouraging sales results for the first nine months of 2014.
AGN: 186.16 (+6.91), SHPG: 185.80 (+1.21), NVS: 88.61 (+0.71)
